Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive
Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.
62/435
Coincidencias para
“Type 2 Diabetes Mellitus”
-
Glycogenic hepatopathy. Review
…associated with uncontrolled diabetes mellitus, most commonly type 1, expressed as right…
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
…be less accurate in type 2 diabetes mellitus (T2DM). We aimed to…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
…panels in patients with type 2 diabetes mellitus (T2DM). All patients underwent…
-
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
…assessed in patients with type 2 diabetes mellitus (T2DM). ### Research Design And…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
…Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM…
-
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
…in unselected patients with type 2 diabetes. ### Design, Setting And Participants Two…
-
Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
…Type-2 diabetes provides an interesting model for assessing liver steatosis. Clinico…
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
…LVDD) in patients with type 2 diabetes mellitus (T2DM). **Methods**: This single…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
…with the pandemic of type 2 diabetes. Here, the authors aimed to…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication
…risk in individuals with type 2 diabetes (T2D). The primary objective of…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Key publication
…calcification in individuals with type 2 diabetes (T2D) remains unclear. This study…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
…needs in patients with type 2 diabetes mellitus (T2DM) is the prediction…
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
…Type 2 diabetes. ### Methods A total of 179 people with Type 2…
-
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
…Consecutive patients with type 1 or 2 diabetes had clinical, biological parameters…
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication
…type-2-diabetes in comparison with patients without type-2-diabetes. These…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
…their caffeine from coffee (50.2% vs. 43.0%; P = .035). Hepatoprotective…
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
…1.86-6.54 versus OR(adjusted advanced inflammatory activity) = 2.23…
-
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
…study including participants with type 2 diabetes and/or obesity and MASLD…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
…3, alcohol consumption, and type 2 diabetes mellitus. ### Conclusions The results showed…
-
Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.
-
The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
…if abnormalities in at least 2 tests (serial PIIINP, TE, or FibroTest…
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
…or without type 2 diabetes mellitus (T2DM), alpha-2 macroglobulin (A2M), apolipoprotein…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
…In type-2 diabetes, FibroTest predicted cardiovascular events and improved the Framingham…
-
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
### Background Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients…
-
The non-invasive assessment of hepatic fibrosis. Review
…type methods for the evaluation of hepatic fibrosis; usually, there are 2…
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
…mortality (Hazard ratio [95% CI]: 2.75 [1.26; 6.03]) than…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
…cohort, 286 outpatients with type 2 diabetes, and in six previously published…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication
…tests in patients with type 2 diabetes (T2D) using the intention-to…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
…White male methadone-users had 2.1-fold excess advanced inflammation risk…
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
…2% had hypertransaminasemia. The percent of patients with overweight, obesity, diabetes, hypertension…
-
Silymarin in non alcoholic fatty liver disease.
### Aim This study was undertaken to evaluate the hepatic effects of silybum…
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…
-
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
…08 for simple steatosis, and 2.80 and 0.18 for NASH…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
…kg/m^2^. Concomitantly, significant improvements in triglycerides, ALT, diabetes markers and…
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
…52.5% with F4 NASH, 40% male, 72% with type 2 diabetes…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
…prevalence - the highest being for type 2 diabetics: advanced steatosis 66%, NASH…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
…2.3±1.8; 3±2.6 and 3.8±2.7…
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…
-
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
…Most subjects (84.2%) with FLI < 60 had S0 and none had…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
…hazardous alcohol use, or type 2 diabetes, reported higher prevalence of advanced…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
…Americans [odds ratio (OR)(adj)=2.08; 95% confidence interval (CI),0…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
…Complicated syndromes often accompanied by obesity and diabetes makes no standard treatment…
-
HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Acute hepatitis C virus infection remains a major health concern in human…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
To assess the accuracy of the noninvasive tools, fibrotest (FT) and liver…
-
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
…diagnose significant fibrosis (F > or = 2 by METAVIR) and cirrhosis (F4 by…
-
Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
…Eleven of the 33 patients had scores ≤0.2, 6 had significant…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
…aspartate aminotransferase/alanine aminotransferase ratio, diabetes score (BARD score), FibroMeter, FibroTest, enhanced…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.